SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing significant volatility and upward momentum driven by intense short-squeeze dynamics, with investors closely watching a recent SEC filing regarding executive change-of-control agreements as a potential precursor to a buyout. The community is heavily focused on the scarcity of available shares, high borrow rates, and the anticipation of topline results from the Phase 3 REGAL trial for their lead AML immunotherapy.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending following news that the FDA has scheduled an advisory committee meeting for its DMD therapy, a development that triggered short-term volatility as traders de-risked ahead of the upcoming decision date. Despite the market's reaction, the community remains heavily focused on the company's strong five-year clinical data, viewing the meeting as a potential opportunity to secure a broader product label rather than a sign of rejection.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is seeing heavy community debate as investors weigh the stock's multi-year lows against potential catalysts like tariff refunds and an upcoming leadership transition. While some traders are betting on a turnaround ahead of earnings, others remain cautious of structural issues and negative analyst sentiment.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is currently seeing high volatility and intense community discussion as investors weigh promising Ibsrela growth and strong fundamentals against persistent legal and reimbursement headwinds from the CMS bundling dispute. While some shareholders remain bullish on the long-term potential for profitability and acquisition, others are expressing frustration over stagnant price action and the ongoing regulatory uncertainty.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently seeing intense community debate and volatility, driven by ongoing efforts to position its solid oxide fuel cell technology as a critical, on-site energy solution for power-hungry AI data centers. Investors remain sharply divided between those viewing recent pullbacks as a buying opportunity based on long-term AI infrastructure backlogs and those expressing skepticism over the stock's valuation, share dilution, and the competitive threat from other energy alternatives.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum and bullish sentiment following a strong earnings report, with the community celebrating the company's shift toward high-growth software and QNX-powered physical AI. Investors are actively discussing upcoming catalyst opportunities and potential institutional re-ratings, pushing back against skeptics while maintaining conviction in the long-term turnaround.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as investors react to a new $6 billion share repurchase program, signaling management's confidence despite ongoing cyclical pressures in automotive and industrial markets. The community remains focused on the stock's potential for a long-term rebound, closely monitoring its performance as it navigates support levels and potential technical breakouts.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing heightened volatility and investor speculation as the market anticipates the potential allocation of FDA priority vouchers following recent executive orders supporting psychedelic therapy. The community is closely monitoring trial milestones for lead assets like BPL-003 and actively debating the stock's valuation disconnect and potential for a strategic partnership or buyout.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors react to a significant strategic agreement with Fit Energy to provide up to 380 megawatts of clean, on-site power for AI data centers. The community remains sharply divided between bulls pointing to the growing proposal pipeline and data center demand, and skeptics who are raising concerns over warrant structures, potential shareholder dilution, and the opacity of the partner involved.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant volatility driven by the positive reception of its long-term oncology trial data and a fresh FDA endorsement for its mRNA-based influenza vaccine candidate. While shareholders and the community are actively debating the company's transition beyond COVID-19 and the potential for a short squeeze, some remain skeptical, citing persistent concerns over regulatory headwinds and the long-term commercialization strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DarioHealth (DRIO) Upgraded to Buy: Here's Why

DarioHealth (DRIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform

Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital...

Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives

Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching...

DarioHealth Q1 Earnings Call Highlights

DarioHealth Q1 Earnings Call Highlights...

DarioHealth Reports Q1 2026 Results: Full Earnings Call Transcript

DarioHealth Reports Q1 2026 Results: Full Earnings Call Transcript...

DarioHealth Corp. (DRIO) Reports Q1 Loss, Beats Revenue Estimates

DarioHealth (DRIO) delivered earnings and revenue surprises of -14.09% and +0.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates

Stereotaxis (STXS) delivered earnings and revenue surprises of +25.00% and -30.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Encompass Health to Expand Idaho Presence With New 50-Bed Facility

EHC plans a new 50-bed inpatient rehab hospital in Post Falls, expanding its footprint in an underserved market with an expected 2028 opening.

Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of +41.18% and +2.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems (DCTH) delivered earnings and revenue surprises of -200.00% and -0.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

This account has been verified as an official DRIO representative.

Verified Account

DarioHealth Corp

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.22	--	--	N/A
Q1 '26	-$1.48	-$1.25	15.54%	BEAT
Q4 '25	-$3.24	-$2.27	30.07%	BEAT
Q3 '25	-$4.90	-$2.96	39.59%	BEAT
Q2 '25	-$0.23	-$3.60	-1442.86%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

DRIODarioHealth Corp

Upcoming Earnings: Q2 '26

Historical Earnings

Latest DRIO News